Name (Synonyms) | Correlation | |
---|---|---|
drug2328 | Standard of care for SARS-CoV-2 infection Wiki | 1.00 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Phase I / II multicentre, randomized and controlled clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection.
Description: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE).
Measure: Safety: Incidence of Adverse Events and Serious Adverse Events grade 3 and 4, related to the product under investigation or the administration procedure, graduated according to the common toxicity criteria scale (CTCAE). Time: 30 days after enrollmentDescription: IL-6> 80 pg / mL, D-dimer> 10 times, ferritin> 1000 ng / mL.
Measure: Efficacy: Any of the following analytical data after 72h of randomization. Time: Day +21 after randomizationDescription: IL-6> 80 pg / mL, D-dimer> 10 times, ferritin> 1000 ng / mL until the cure test.
Measure: Efficacy: Proportion of patients who develop analytical alterations. Time: Day +21 after randomization.Description: Proportion of patients requiring treatment with Tocilizumab Sarilumab, Anakimra or other IL-6 or IL-1 antagonists, or corticosteroids at doses of methylprednisolone greater than 2 mg / Kg / day (or equivalent) and / or any investigational medication.
Measure: Efficacy: Proportion of patients requiring treatment. Time: Until day 21.